Home >> Research Area >>Tyrosine Kinase/Adaptors>>FGFR>> Dovitinib (TKI-258, CHIR-258)

Dovitinib (TKI-258, CHIR-258)

Multitargeted RTK inhibitor CAS# 405169-16-6

Dovitinib (TKI-258, CHIR-258)

Catalog No. BCC1169----Order now to get a substantial discount!

Product Name & Size Price Stock
Dovitinib (TKI-258, CHIR-258): 5mg $58 In Stock
Dovitinib (TKI-258, CHIR-258): 10mg Please Inquire In Stock
Dovitinib (TKI-258, CHIR-258): 20mg Please Inquire Please Inquire
Dovitinib (TKI-258, CHIR-258): 50mg Please Inquire Please Inquire
Dovitinib (TKI-258, CHIR-258): 100mg Please Inquire Please Inquire
Dovitinib (TKI-258, CHIR-258): 200mg Please Inquire Please Inquire
Dovitinib (TKI-258, CHIR-258): 500mg Please Inquire Please Inquire
Dovitinib (TKI-258, CHIR-258): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Dovitinib (TKI-258, CHIR-258)

Number of papers citing our products

Chemical structure

Dovitinib (TKI-258, CHIR-258)

3D structure

Chemical Properties of Dovitinib (TKI-258, CHIR-258)

Cas No. 405169-16-6 SDF Download SDF
PubChem ID 9977819 Appearance Powder
Formula C21H21FN6O M.Wt 392.43
Type of Compound N/A Storage Desiccate at -20°C
Synonyms CHIR-258; TKI258
Solubility DMSO : 25 mg/mL (63.71 mM; Need ultrasonic and warming)
Chemical Name (3E)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one
SMILES CN1CCN(CC1)C2=CC3=C(C=C2)NC(=C4C(=C5C(=NC4=O)C=CC=C5F)N)N3
Standard InChIKey KCOYQXZDFIIGCY-CZIZESTLSA-N
Standard InChI InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11,24-25H,7-10,23H2,1H3/b20-18+
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Dovitinib (TKI-258, CHIR-258)

DescriptionDovitinib is a multitargeted inhibitor of RTK with IC50 values of 1 nM, 2 nM and 8 nM for FLT3, c-Kit and FGFR1, respectively.
TargetsFLT3c-KitFGFR1VEGFR3/FLT4FGFR3VEGFR1/FLT1
IC501 nM2 nM8 nM8 nM9 nM10 nM

Protocol

Kinase experiment [1]:

Inhibitory activities

IC50 values for the inhibition of RTKs by CHIR-258 were determined in a time-resolved fluorescence (TRF) or radioactive format, measuring the inhibition by CHIR-258 of phosphate transfer to a substrate by the respective enzyme. The kinase domains of FGFR3, FGFR1, PDGFR-β and VEGFR1-3 were assayed in 50 mM HEPES (N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid), pH 7.0, 2 mM MgCl2, 10 mM MnCl2, 1 mM NaF, 1 mM dithiothreitol (DTT), 1 mg/mL bovine serum albumin (BSA), 0.25 μM biotinylated peptide substrate (GGGGQDGKDYIVLPI), and 1 to 30 μM adenosine triphosphate (ATP) depending on the Km for the respective enzyme. ATP concentrations were at or just below Km. For c-KIT and FLT3 reactions the pH was raised to 7.5 with 0.2 to 8 μM ATP in the presence of 0.25 to 1 μM biotinylated peptide substrate (GGLFDDPSYVNVQNL). Reactions were incubated at room temperature for 1 to 4 hours and the phosphorylated peptide captured on streptavidin-coated microtiter plates containing stop reaction buffer (25 mM EDTA, 50mM HEPES, pH 7.5).

Cell experiment [1]:

Cell lines

Human multiple myeloma (MM) cell lines and B9 cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

100 nM CHIR-258; 48-96 h.

Applications

Dovitinib is a receptor tyrosine kinases inhibitor. Dovitinib selectively inhibits the growth of human myeloma cell lines and B9 cells expressing wild-type (WT) or activated mutant FGFR3. Dovitinib also causes cytostatic and cytotoxic effects and inhibits downstream extracellular signal-regulated kinase (ERK) 1/2 phosphorylation.

Animal experiment [1]:

Animal models

6- to 8-week-old female BNX mice bearing 3 ×107 KMS11 cells.

Dosage form

10, 30, or 60 mg/kg for 21 days by gavage.

Preparation method

Dissolved in dimethyl sulfoxide (DMSO) at a stock concentration of 20 mM. For animal experiments: formulated in 5 mM citrate buffer.

Application

Dovitinib causes antitumor effect and inhibits tumor growths by 48%, 78.5%, and 94% in the 10 mg/kg, 30 mg/kg, and 60 mg/kg treatment arms, respectively. Weight loss, as a marker of significant toxicity, is not observed in any of the treatment groups. Dovitinib completely inhibits FGFR3 at the 60 mg/kg dose. CHIR-258 induces both cytostatic and cytotoxic responses.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood, 2005, 105(7): 2941-2948.

Dovitinib (TKI-258, CHIR-258) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Dovitinib (TKI-258, CHIR-258) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Dovitinib (TKI-258, CHIR-258)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.5482 mL 12.7411 mL 25.4823 mL 50.9645 mL 63.7056 mL
5 mM 0.5096 mL 2.5482 mL 5.0965 mL 10.1929 mL 12.7411 mL
10 mM 0.2548 mL 1.2741 mL 2.5482 mL 5.0965 mL 6.3706 mL
50 mM 0.051 mL 0.2548 mL 0.5096 mL 1.0193 mL 1.2741 mL
100 mM 0.0255 mL 0.1274 mL 0.2548 mL 0.5096 mL 0.6371 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Dovitinib (TKI-258, CHIR-258)

Dovitinib (TKI258, CHIR-258) is a multitargeted receptor tyrosine kinase inhibitor against FLT3, KIT, FGFR, VEGFR, PDGFRα and PDGFRβ with IC50 of 1 nM, 2 nM, 8-9 nM, 8-13 nM , 210 nM and 27nM, respectively [1].

The viability of ZNF198-FGFR1 or BCR-FGFR1 cells was specifically inhibited by TKI258 with IC50 values of 150 nM or 90 nM. The phosphorylation of ERK and STAT5 genes was inhibited by TKI258 in dose dependent manner. TKI258 also specifically inhibited proliferation and survival of the FGFR1OP2-FGFR1-positive KG1 and KG1A cell lines, increasing levels of apoptosis [2]. In hepatocellular carcinoma (HCC) cells, the combination of TKI258 and tigatuzumab restored the sensitivity of HCC cells to TRAIL- and tigatuzumab-induced apoptosis. TKI258 inhibited phosphorylation of STAT3 and subsequently reduced the protein levels of Mcl-1, Survivin and Cylcin D1. Co-treatment of TRAIL and TKI258 increased the activity of SHP-1 [3]. Inhibition of FGFR3 with TKI258 decreased waldenstr?m macroglobulinemia (WM) cell survival, increased apoptosis, and induced cell cycle arrest. TKI258 reduced the interaction of WM to bone marrow element, and reversed its proliferation. TKI258 had an additive effect with other drugs [4].

In vivo, the combination of tigatuzumab and TKI258 inhibited Huh-7 xenograft tumor growth [3]. TKI258 reduced WM tumor progression [4].

References:
[1]. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005 Apr 1;105(7):2941-8.
[2]. Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 2007 Nov 15;110(10):3729-34.
[3]. Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ, Cheng AL. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochem Pharmacol. 2012 Mar 15;83(6):769-77.
[4]. Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, Roccaro AM, Ghobrial IM. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res. 2011 Jul 1;17(13):4389-99.

Featured Products
New Products
  • NFPS

    Catalog No.:BCC7484
    CAS No.:405225-21-0
  • Dadahol A

    Catalog No.:BCN5457
    CAS No.:405281-76-7
  • Cyclapolin 9

    Catalog No.:BCC7571
    CAS No.:40533-25-3
  • SB590885

    Catalog No.:BCC4392
    CAS No.:405554-55-4
  • GW3965

    Catalog No.:BCC1612
    CAS No.:405911-09-3
  • GW3965 HCl

    Catalog No.:BCC3790
    CAS No.:405911-17-3
  • C34

    Catalog No.:BCC5603
    CAS No.:40592-88-9
  • Cirazoline hydrochloride

    Catalog No.:BCC6833
    CAS No.:40600-13-3
  • DMT-Cl

    Catalog No.:BCC2799
    CAS No.:40615-36-9
  • DMT-T

    Catalog No.:BCC2843
    CAS No.:40615-39-2
  • DSP-4

    Catalog No.:BCC7527
    CAS No.:40616-75-9
  • ACHP

    Catalog No.:BCC6223
    CAS No.:406208-42-2
 

References on Dovitinib (TKI-258, CHIR-258)

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(-) breast cancer that had progressed during or after prior endocrine therapy.[Pubmed:28183331]

Breast Cancer Res. 2017 Feb 10;19(1):18.

BACKGROUND: Overexpression of fibroblast growth factor receptor 1 (FGFR1), found in

Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications.[Pubmed:28342996]

Transl Oncol. 2017 Jun;10(3):357-366.

Prostate cancer (PCa) remains the second-leading cause of cancer-related deaths in American men with an estimated mortality of more than 26,000 in 2016 alone. Aggressive and metastatic tumors are treated with androgen deprivation therapies (ADT); however, the tumors acquire resistance and develop into lethal castration resistant prostate cancer (CRPC). With the advent of better therapeutics, the incidences of a more aggressive neuroendocrine prostate cancer (NEPC) variant continue to emerge. Although de novo occurrences of NEPC are rare, more than 25% of the therapy-resistant patients on highly potent new-generation anti-androgen therapies end up with NEPC. This, along with previous observations of an increase in the number of such NE cells in aggressive tumors, has been suggested as a mechanism of resistance development during prostate cancer progression. Dovitinib (TKI-258/CHIR-258) is a pan receptor tyrosine kinase (RTK) inhibitor that targets VEGFR, FGFR, PDGFR, and KIT. It has shown efficacy in mouse-model of PCa bone metastasis, and is presently in clinical trials for several cancers. We observed that both androgen receptor (AR) positive and AR-negative PCa cells differentiate into a NE phenotype upon treatment with Dovitinib. The NE differentiation was also observed when mice harboring PC3-xenografted tumors were systemically treated with Dovitinib. The mechanistic underpinnings of this differentiation are unclear, but seem to be supported through MAPK-, PI3K-, and Wnt-signaling pathways. Further elucidation of the differentiation process will enable the identification of alternative salvage or combination therapies to overcome the potential resistance development.

Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.[Pubmed:27681579]

Cancer Chemother Pharmacol. 2016 Nov;78(5):921-927.

PURPOSE: A capsule formulation of the tyrosine kinase inhibitor dovitinib (TKI258) was recently studied in a phase 3 renal cell carcinoma trial; however, tablets are the planned commercial formulation. Therefore, this randomized 2-way crossover study evaluated the bioequivalence of dovitinib tablet and capsule formulations in pretreated patients with advanced solid tumors, excluding breast cancer. METHODS: In this 2-part study, eligible patients received dovitinib 500 mg once daily on a 5-days-on/2-days-off schedule. During the 2-period bioequivalence phase, patients received their initial formulation (capsule or tablet) for 3 weeks before being switched to the alternative formulation in the second period. Patients could continue to receive dovitinib capsules on the same dosing schedule during the post-bioequivalence phase. RESULTS: A total of 173 patients were enrolled into the bioequivalence phase of the study (capsule --> tablet, n = 88; tablet --> capsule, n = 85), and 69 patients had evaluable pharmacokinetics (PK) for both periods. PK analyses showed similar exposure and PK profiles for the dovitinib capsule and tablet formulations and supported bioequivalence [geometric mean ratios: AUClast, 0.95 (90 % CI 0.88-1.01); C max, 0.98 (90 % CI 0.91-1.05)]. The most common adverse events, suspected to be study drug related, included diarrhea (60 %), nausea (53 %), fatigue (45 %), and vomiting (43 %). Of 168 patients evaluable for response, 1 achieved a partial response, and stable disease was observed in 32 % of patients. CONCLUSIONS: Dovitinib capsules and tablets were bioequivalent, with a safety profile similar to that observed in other dovitinib studies of patients with heavily pretreated advanced solid tumors.

Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma.[Pubmed:28714373]

Tumour Biol. 2017 Jul;39(7):1010428317707372.

Renal cell carcinoma, the most common neoplasm of adult kidney, accounts for about 3% of adult malignancies and is usually highly resistant to conventional therapy. MicroRNAs are a class of small non-coding RNAs, which have been previously shown to promote malignant initiation and progression. In this study, we focused our attention on miR-21, a well described oncomiR commonly upregulated in cancer. Using a cohort of 99 primary renal cell carcinoma samples, we showed that miR-21 expression in cancer tissues was higher than in adjacent non-tumor tissues whereas no significant difference was observed with stages, grades, and metastatic outcome. In vitro, miR-21 was also overexpressed in renal carcinoma cell lines compared to HK-2 human proximal tubule epithelial cell line. Moreover, using Boyden chambers and western blot techniques, we also showed that miR-21 overexpression increased migratory, invasive, proliferative, and anti-apoptotic signaling pathways whereas opposite results were observed using an anti-miR-21-based silencing strategy. Finally, we assessed the role of miR-21 in mediating renal cell carcinoma chemoresistance and further showed that miR-21 silencing significantly (1) increased chemosensitivity of paclitaxel, 5-fluorouracil, oxaliplatin, and dovitinib; (2) decreased expression of multi-drug resistance genes; and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression. In conclusion, our results showed that miR-21 is a key actor of renal cancer progression and plays an important role in the resistance to chemotherapeutic drugs. In renal cell carcinoma, targeting miR-21 is a potential new therapeutic strategy to improve chemotherapy efficacy and consequently patient outcome.

Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPRFGFR1 fusion.[Pubmed:28138694]

Mol Med Rep. 2017 Mar;15(3):1024-1030.

8p11 myeloproliferative syndrome (EMS) is a rare disease characterized by the constitutive activation of fibroblast growth factor receptor 1 (FGFR1). To date, four cases of EMS with the chromosomal translocation, t(1;8)(q25;p11.2), have been reported. In the present study, TPRFGFR1expressing Baf3 cells were established and confirmed by polymerase chain reaction. To identify the most promising drug for EMS, the activities and associated mechanism of three tyrosine kinase inhibitors (TKIs), TKI258, ponatinib and AZD4547, against TPRFGFR1 were tested by MTT assay, flow cytometry and western blot. The data demonstrated that TPRFGFR1 was localized in the cytoplasm, and was able to transform interleukin-3-dependent hematopoietic Baf3 cells into growth factorindependent cells. All of the three TKIs markedly inhibited the proliferation of TPRFGFR1expressing Baf3 cells, and the activation of FGFR1 and the downstream signaling molecules, extracellular signalregulated kinase 1/2, phospholipiase Cgamma and signal transducer and activator of transcription 5. AZD4547 was the most efficient drug, and TKI258 was the least. By contrast, no significant difference was found among the three drugs on their effect on cell apoptosis. Taken together, the data obtained in the present study suggested that AZD4547 had increased potency, compared with TKI258 and ponatinib, for the treatment of EMS.

Description

Dovitinib (TKI258; CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.

Keywords:

Dovitinib (TKI-258, CHIR-258),405169-16-6,CHIR-258; TKI258,Natural Products,FGFR, buy Dovitinib (TKI-258, CHIR-258) , Dovitinib (TKI-258, CHIR-258) supplier , purchase Dovitinib (TKI-258, CHIR-258) , Dovitinib (TKI-258, CHIR-258) cost , Dovitinib (TKI-258, CHIR-258) manufacturer , order Dovitinib (TKI-258, CHIR-258) , high purity Dovitinib (TKI-258, CHIR-258)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: